ArticleThe Journal of clinical investigation2013
Parthenogenetic stem cells for tissue-engineered heart repair.
Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.
- ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure.Cardiovascular research · 2019Guideline
- Artificial activation of clinically failed human oocytes enables euploid blastocyst formation.Journal of assisted reproduction and genetics · 2026Article
- Trials and tribulations of cell therapy for heart failure: an update on ongoing trials.Nature reviews. Cardiology · 2025Review
- Article
- Advances in the design, generation, and application of tissue-engineered myocardial equivalents.Frontiers in bioengineering and biotechnology · 2023Review
- Bioengineering approaches to treat the failing heart: from cell biology to 3D printing.Nature reviews. Cardiology · 2022Review
- The Insulin-like Growth Factor Signalling Pathway in Cardiac Development and Regeneration.International journal of molecular sciences · 2021Review
- Generation of developmentally competent oocytes and fertile mice from parthenogenetic embryonic stem cells.Protein & cell · 2021Article
- Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2021Review
- The Dynamic Changes of Transcription Factors During the Development Processes of Human Biparental and Uniparental Embryos.Frontiers in cell and developmental biology · 2021Article
- Understanding the Adult Mammalian Heart at Single-Cell RNA-Seq Resolution.Frontiers in cell and developmental biology · 2021Review
- Regulation of cardiomyocyte maturation during critical perinatal window.The Journal of physiology · 2020Review
- Insulin-like growth factor-II overexpression accelerates parthenogenetic stem cell differentiation into cardiomyocytes and improves cardiac function after acute myocardial infarction in mice.Stem cell research & therapy · 2020Article
- Is Human-induced Pluripotent Stem Cell the Best Optimal?Chinese medical journal · 2018Review
- Review
- Mouse Parthenogenetic Embryonic Stem Cells with Biparental-Like Expression of Imprinted Genes Generate Cortical-Like Neurons That Integrate into the Injured Adult Cerebral Cortex.Stem cells (Dayton, Ohio) · 2018Article
- Germline Stem Cells in Myocardial Regeneration - A new hope worth a delve.Journal of stem cells & regenerative medicine · 2018Article
- Alterations of protein glycosylation in embryonic stem cells during adipogenesis.International journal of molecular medicine · 2018Article
- Myocardial Tissue Engineering for Regenerative Applications.Current cardiology reports · 2017Review
- Engineered Heart Repair.Clinical pharmacology and therapeutics · 2017Review
Corrections and comments
- Commented on by
Authors and funding
31 authors at 10 institutions in 3 countries.
Funding
Abstract
Uniparental parthenotes are considered an unwanted byproduct of in vitro fertilization. In utero parthenote development is severely compromised by defective organogenesis and in particular by defective cardiogenesis. Although developmentally compromised, apparently pluripotent stem cells can be derived from parthenogenetic blastocysts. Here we hypothesized that nonembryonic parthenogenetic stem cells (PSCs) can be directed toward the cardiac lineage and applied to tissue-engineered heart repair. We first confirmed similar fundamental properties in murine PSCs and embryonic stem cells (ESCs), despite notable differences in genetic (allelic variability) and epigenetic (differential imprinting) characteristics. Haploidentity of major histocompatibility complexes (MHCs) in PSCs is particularly attractive for allogeneic cell-based therapies. Accordingly, we confirmed acceptance of PSCs in MHC-matched allotransplantation. Cardiomyocyte derivation from PSCs and ESCs was equally effective. The use of cardiomyocyte-restricted GFP enabled cell sorting and documentation of advanced structural and functional maturation in vitro and in vivo. This included seamless electrical integration of PSC-derived cardiomyocytes into recipient myocardium. Finally, we enriched cardiomyocytes to facilitate engineering of force-generating myocardium and demonstrated the utility of this technique in enhancing regional myocardial function after myocardial infarction. Collectively, our data demonstrate pluripotency, with unrestricted cardiogenicity in PSCs, and introduce this unique cell type as an attractive source for tissue-engineered heart repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.